Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 8/20 | 0.82 |
| ▸ | ABL1 | P00519 | 11/20 | 0.76 |
| ▸ | CSF1R | P07333 | 1/20 | 0.71 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.71 |
| ▸ | SRC | P12931 | 1/20 | 0.70 |
| ▸ | FLT3 | P36888 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24626017 | 1.00 | KIT (0.82) | KITABL1CSF1RFGFR1KDR | |
| SCHEMBL13765822 | 0.93 | KIT (0.71) | KITABL1CSF1RFGFR1KDR | |
| SCHEMBL15006468 | 0.92 | KIT (0.70) | KITABL1FGFR1FLT3 | |
| SCHEMBL4097590 | 0.90 | ABL1 (0.74) | KITABL1FGFR1FLT3 | |
| SCHEMBL19322509 | 0.90 | KIT (0.79) | KITABL1CSF1RFGFR1KDR | |
| SCHEMBL22548956 | 0.90 | ABL1 (0.82) | KITABL1 | |
| SCHEMBL31620766 | 0.90 | KIT (1.00) | KITABL1FGFR1FLT3 | |
| SCHEMBL29675009 | 0.89 | KIT (0.78) | KITABL1CSF1RFGFR1KDR | |
| SCHEMBL24626792 | 0.89 | KIT (0.78) | KITABL1CSF1RFGFR1KDR | |
| SCHEMBL24626018 | 0.88 | KIT (0.77) | KITABL1CSF1RFGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022149855-A1 | HETEROARYL-ETHYNYL DERIVATIVE COMPOUND AND USE THEREOF | 주식회사 비투에스바이오 | 2022-07-14 | — | — | WO | claimed |
| WO-2022149855-A1 | HETEROARYL-ETHYNYL DERIVATIVE COMPOUND AND USE THEREOF | 주식회사 비투에스바이오 | 2022-07-14 | — | — | WO | disclosed |